ResMed (RMD) is a global leader in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD) and other chronic diseases. SDB includes obstructive sleep apnoea (OSA), and other respiratory disorders that occur during sleep. The company’s products and solutions are designed to improve patient quality of life, reduce the impact of chronic disease and lower healthcare costs as global healthcare systems continue to drive a shift in care from hospitals to the home and lower cost settings. ResMed’s cloud-based software digital health applications, along with its devices, are designed to provide connected care to improve patient outcomes and efficiencies for their customers. ResMed employs about 5,000 employees worldwide, operates in 100 countries and has manufacturing facilities in Australia, France, Singapore and the US. The ResMed share price is available at Capital.com.
最新股票文章

為何麥可·貝瑞(Michael Burry)剛剛清倉所有股票
麥可·貝瑞剛剛拋售了超過7,000萬美元的股票,清空了他的整個投資組合,只保留一支股票,並對這家公司加碼,而其他投資人則紛紛出逃。
18:37, 22 7月 2025